

CS Pharmaceuticals Announces Acquisition of Exclusive Chinese Commercialisation Rights to BRONCHITOL® from Pharmaxis

- *Cystic fibrosis treatment approved in over 30 countries including US and EU -*
- *Product to leverage CS Pharmaceuticals' dedicated commercial platform in China -*

LONDON, England and BEIJING and SHANGHAI, China – February 15 2022 – CS Pharmaceuticals Limited (CSP), the pharmaceutical licensing partner dedicated to speciality and rare disease product development and commercialisation in China, today announces the acquisition of the exclusive Chinese commercial rights to BRONCHITOL® from Pharmaxis. BRONCHITOL® is currently approved for the treatment of cystic fibrosis in over 30 countries, including the USA, European Union, UK, Switzerland and Australia. CSP intends to seek priority review and approval in China, leveraging the product's extensive phase III database, prior to commercialisation in this potentially significant market. Currently there are no treatments approved for cystic fibrosis in China, with Western products such as CFTR modulator therapies specifically designed and licensed for common Caucasian gene mutations associated with the disease rather than the specific mutations found in Chinese subjects.

Darren Mercer, CS Pharmaceuticals' Chief Executive, said: "The acquisition of the Chinese commercial rights to BRONCHITOL® is transformative for CS Pharmaceuticals as it marks the formal launch of our development and commercialization platform in China. Since the establishment of CSP in 2021, our team of experts has worked rapidly to build our dedicated market access, commercial, medical and compliance capabilities, and the licensing of these product rights validates our unique business model focused on bringing speciality and rare disease Western medicines to Chinese patients. With this transaction now successfully completed, we look forward to continuing the expansion of CSP's portfolio, as we help our partners bring their speciality products to China to address the unmet medical needs of Chinese patients."

About BRONCHITOL®

BRONCHITOL® is a precision spray-dried formulation of mannitol, which is delivered to the lungs via a specially designed, portable inhaler. It is approved in the treatment of cystic fibrosis in over 30 countries and has successfully completed three large-scale phase III clinical trials. The data from these show that BRONCHITOL® helps increase mucus clearance and improves lung function and quality of life in cystic fibrosis patients. Cystic fibrosis is greatly under-recognised in China, with few cases diagnosed. However, the carrier frequency in the population suggests over 20,000 patients may have the disease, representing a significant potential market addressable through CS Pharmaceuticals' speciality commercialisation capabilities.

About CS Pharmaceuticals

CS Pharmaceuticals (CSP) is a British multinational pharmaceutical company focused on licensing Chinese commercialisation rights to Western rare disease and speciality medicines. The company, with its headquarters in London and offices in Beijing and Shanghai, offers dedicated regulatory, market access, medical and commercial expertise, in addition to international-standard compliance and legal capabilities. The team has an impressive track record of success in China, providing partners with significant experience in this fast-growing market. With its dedicated commercialisation platform, CSP is rapidly becoming a 'go-to' trusted licensing partner,



expanding its portfolio of innovative rare disease and ophthalmology assets while making business easier for companies wishing to develop and commercialize their products in China.

www.cspharmaceuticals.com

Contacts

CS Pharmaceuticals
Darren Mercer, Chief Executive Officer

Tel: +44 (0) 2037 534691

